Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor

David A. Bushinsky,Geoffrey A. Block,Kevin J. Martin,Gregory Bell,Saling Huang,Yan Sun,David Spiegel,Liron Walsh,T. Christian H. Mix,Reshma Kewalramani

Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor

2015

David A. Bushinsky
Geoffrey A. Block
Kevin J. Martin
Gregory Bell
Saling Huang
Yan Sun
David Spiegel
Liron Walsh
T. Christian H. Mix
Reshma Kewalramani

Background/Aims: This study evaluated the efficacy and safety of AMG416 (etelcalcitide), a novel peptide agonist of the calcium (Ca)-sensing receptor given intrav

Keywords:

Calcium
Calcium-sensing receptor
Fibroblast growth factor 23
Internal medicine
Parathyroid hormone
Secondary hyperparathyroidism
Endocrinology
Agonist
Receptor
Medicine
Peptide
Diabetes mellitus
Etelcalcetide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations